Close



Apr 5, 2024 06:00AM
Mar 28, 2024 10:15AM
Mar 25, 2024 09:00PM
Mar 21, 2024 09:00PM
Mar 19, 2024 10:45AM
Mar 17, 2024 09:00PM
Mar 14, 2024 12:00PM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
Mar 12, 2024 09:00PM
Mar 8, 2024 11:30PM
Mar 7, 2024 10:15AM
Mar 4, 2024 09:00PM
Mar 1, 2024 10:15AM
Feb 29, 2024 09:00PM
Feb 28, 2024 09:15AM Cassava Sciences (SAVA) Reports FY23 Nets Loss of $97.2M, Provides Corporate Update
Feb 28, 2024 09:14AM
Feb 25, 2024 09:00PM
Feb 23, 2024 11:30AM
Feb 21, 2024 09:00PM
Feb 17, 2024 09:00PM
Feb 13, 2024 09:00PM
Feb 9, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brooge, and Cassava and Encourages Investors to Contact the Firm
Feb 8, 2024 11:02AM
Feb 5, 2024 09:00PM
Nov 6, 2023 09:15AM
Oct 2, 2023 09:05AM
Oct 2, 2023 09:00AM
Sep 18, 2023 09:15AM
Sep 18, 2023 09:15AM Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
Sep 11, 2023 09:10AM
Sep 11, 2023 09:10AM
Aug 3, 2023 09:09AM
Aug 3, 2023 09:07AM
Jul 5, 2023 09:15AM
Jul 5, 2023 09:15AM
May 8, 2023 09:16AM Cassava Sciences (SAVA) Announces New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
May 8, 2023 09:15AM
May 1, 2023 09:00AM
May 1, 2023 09:00AM
Feb 28, 2023 09:16AM
Feb 28, 2023 09:15AM
Feb 28, 2023 09:15AM
Feb 8, 2023 09:15AM Cassava Sciences (SAVA) Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Feb 8, 2023 09:15AM
Feb 8, 2023 09:15AM
Jan 24, 2023 09:15AM
Jan 24, 2023 09:15AM
Jan 24, 2023 09:15AM
Dec 6, 2022 09:16AM
Dec 6, 2022 09:15AM Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
Dec 6, 2022 09:15AM

251,413 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All